Zobrazeno 1 - 10
of 167
pro vyhledávání: '"PAULINE FUNCHAIN"'
Autor:
Danai Dima, Nerea Lopetegui‐Lia, Olisaemeka Ogbue, Bennett Osantowski, Fauzia Ullah, Xuefei Jia, Jung Min Song, Brian Gastman, James Isaacs, Lucy Boyce Kennedy, Pauline Funchain
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse,
Externí odkaz:
https://doaj.org/article/00d7e2c1a4e64eb7bb23bb9111e3990d
Autor:
Lukas W Pfannenstiel, Brian R Gastman, Jennifer S Ko, Marc S Ernstoff, Pauline Funchain, Yee Peng Phoon, Jared E Lopes, Heather C Losey, Claudia Marcela Diaz-Montero, Ye F Tian, Raymond Winquist, Jan Joseph Melenhorst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background Despite recent advances in immunotherapy, a substantial population of late-stage melanoma patients still fail to achieve sustained clinical benefit. Lack of translational preclinical models continues to be a major challenge in the field of
Externí odkaz:
https://doaj.org/article/be91f26ce0d14a72a9d770e7782a5e38
Autor:
Vipin Shankar Chelakkot, Kiara Thomas, Todd Romigh, Andrew Fong, Lin Li, Shira Ronen, Shuyang Chen, Pauline Funchain, Ying Ni, Joshua Arbesman
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-13 (2023)
Abstract MC1R, a G-protein coupled receptor, triggers ultraviolet light-induced melanin synthesis and DNA repair in melanocytes and is implicated in the pathogenesis of melanoma. Although widely expressed in different tissue types, its function in no
Externí odkaz:
https://doaj.org/article/7d4fac13360c4223ba07544f175c161d
Autor:
Joshua Longinow, Mohammad Zmaili, Warren Skoza, Nicholas Kondoleon, Robert Marquardt, Cassandra Calabrese, Pauline Funchain, Rohit Moudgil
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2281-2289 (2023)
Abstract Background Immune checkpoint inhibitors can result in overlap syndrome comprised of myasthenia gravis, myositis and myocarditis. However, the mortality predictors have not been clearly delineated. Methods We examined the characteristics of 1
Externí odkaz:
https://doaj.org/article/9ee82cc7c56b4358ac8be43a4cb50e65
Publikováno v:
JAAD International, Vol 11, Iss , Pp 220-221 (2023)
Externí odkaz:
https://doaj.org/article/a356eaa35c254d408befe90140621c96
Autor:
Irene Orlow, Keimya D Sadeghi, Sharon N Edmiston, Jessica M Kenney, Cecilia Lezcano, James S Wilmott, Anne E Cust, Richard A Scolyer, Graham J Mann, Tim K Lee, Hazel Burke, Valerie Jakrot, Ping Shang, Peter M Ferguson, Tawny W Boyce, Jennifer S Ko, Peter Ngo, Pauline Funchain, Judy R Rees, Kelli O'Connell, Honglin Hao, Eloise Parrish, Kathleen Conway, Paul B Googe, David W Ollila, Stergios J Moschos, Eva Hernando, Douglas Hanniford, Diana Argibay, Christopher I Amos, Jeffrey E Lee, Iman Osman, Li Luo, Pei-Fen Kuan, Arshi Aurora, Bonnie E Gould Rothberg, Marcus W Bosenberg, Meg R Gerstenblith, Cheryl Thompson, Paul N Bogner, Ivan P Gorlov, Sheri L Holmen, Elise K Brunsgaard, Yvonne M Saenger, Ronglai Shen, Venkatraman Seshan, Eduardo Nagore, Marc S Ernstoff, Klaus J Busam, Colin B Begg, Nancy E Thomas, Marianne Berwick, InterMEL Consortium
Publikováno v:
PLoS ONE, Vol 18, Iss 4, p e0269324 (2023)
IntroductionWe are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of gener
Externí odkaz:
https://doaj.org/article/2122630446b94345873b74cdda1850a8
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background To evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (
Externí odkaz:
https://doaj.org/article/f7b8e37d15714ca6af0d5972d3347d1f
Autor:
Tapas Ranjan Behera, Jung Min Song, Jennifer Ko, Donald Eicher, Joshua Arbesman, Brian Gastman, Daniel H. Farkas, Pauline Funchain
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Treatment of metastatic melanoma includes the option of targeted therapy in patients with driver BRAF mutations. BRAF-MEK inhibitor drugs improve survival in the approximately 50% of patients with melanoma that harbor BRAF mutations. As BRAF mutation
Externí odkaz:
https://doaj.org/article/03b76a5eb7ff44c0995f116356212541
Autor:
Tapas Ranjan Behera, Jung Min Song, Joshua Arbesman, Jennifer Ko, Jessica Philpott, Pauline Funchain
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 4, Iss , Pp 100091- (2021)
Immune checkpoint inhibitor (ICI) therapy is highly effective in managing several malignancies, however ICI can induce unique toxicities known as immune related adverse events (irAEs). A wide range of dermatologic irAEs including localized lichenoid
Externí odkaz:
https://doaj.org/article/4cc62e19a09f427da6f35e23c95f2c68
Autor:
Rishi Rikhi, Jaret Karnuta, Muzna Hussain, Patrick Collier, Pauline Funchain, Wai Hong Wilson Tang, Timothy A. Chan, Rohit Moudgil
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
The advent of immune checkpoint inhibitors (ICIs) has revolutionized the field of oncology, but these are associated with immune related adverse events. One such adverse event, is myocarditis, which has limited the continued immunosuppressive treatme
Externí odkaz:
https://doaj.org/article/3ba784dc2251421b89a1e261cca9dbc9